Next Phase Newsletter

A corporate venture capital firm invests globally in technologies with potential to impact mortality rates at scale by improving healthcare quality and outcomes to support the parent company’s initiatives. The firm’s fund prioritizes technologies that address acute, time-critical conditions and makes investments internationally. The firm will invest up to $5M USD for their first check with capital reserved to follow on. The firm is actively deploying capital. 
 
The firm invests solely in medical devices, diagnostics, and digital health. The fund does not invest in therapeutics, biotech, pharma, and CROs. The fund looks at acute, time-critical areas of healthcare and is interested in solutions that support prevention, earlier identification and intervention, and improved therapeutics for these conditions. Key areas of focus include, but are not limited to cardiovascular care, sepsis, stroke, trauma and surgery, maternal and neonatal care, emergency medicine, and healthcare education & training. 
 
The firm can act both as a lead and co-investor. The firm needs to see committed and full-time teams with demonstrated product market fit. The fund invests in pre- and post- FDA approval companies, but companies should have an MVP and licensed IP where relevant. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A life science venture capital firm with extensive global access and unique cross-border expertise. The firm discovers, incubates and grows next-generation life science companies in early and growth stage. Their portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs. They operate offices in USA and China. 
 
The firm focuses mostly on novel therapeutics, like small molecule, cell therapy, gene therapy, etc, while the firm is also open to enabling technologies and high-end specialty services. The firm is looking to invest from seed, first institutional round, to growth stage. 
 
The firm has no specific requirement for the company & management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture arm of an international pharmaceutical company is committed to advancing healthcare innovation globally. The firm identifies, supports, and invests in transformative technologies that align with the parent company’s strategic vision of improving health and quality of life. 
 
The firm seeks opportunities in therapeutics, diagnostics, digital health, and medical devices, with a particular emphasis on products and innovations that can expand the parent company’s Women’s Health portfolio. The organization is especially interested in solutions that improve the healthcare journey for women and address gaps in existing therapeutic and diagnostic options. 

The firm is open to collaborations in addition to investments, including partnerships with companies whose products are already on the market and are looking to expand into new geographies. Leveraging the parent company’s extensive global network, the firm aims to help these companies access new markets and scale their impact. 
 
The firm supports management teams with diverse expertise and a strong commitment to innovation. While a proven track record in the life sciences is advantageous, the firm is eager to collaborate with promising teams developing solutions aligned with the parent company’s strategic priorities. The venture is open to co-investment opportunities with partners who share its vision. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm headquartered in Israel typically invests at the earliest stages of pre-seed or seed. The firm aims to promote Jewish-Arab collaboration and support companies in their earliest stages. The firm is currently investing from their second fund and typically makes 5-7 investments per calendar year. The firm has invested in over 20 companies out of this current fund. The firm prefers to invest within Israel, however, the firm is open to making investments globally. 
 
The firm invests in medical device, therapeutics, and diagnostics. The firm is modality- and indication- agnostic. The firm does not invest in digital health. 
 
The firm has no strict team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A U.S.-headquartered multinational life sciences corporation develops, manufactures, and sells reagents, instruments, and provides services for the research, diagnostic, and bioprocessing markets. The firm is actively seeking opportunities aligned with its current pipeline and business, such as life science tools and services, diagnostics, spatial biology, and tech-bio. The firm primarily focuses on mergers and acquisitions, but equity investments are also possible. For equity investments, the sweet spot is around Series A and the firm prefers co-investment opportunities and may seek board or observer seats on a case-by-case basis. The firm is primarily interested in opportunities based in the U.S. and Europe. 
 
The firm is focused on tools and services, diagnostics, spatial biology, and tech-bio, such as platforms that enhance biopharma R&D and academic research. Technologies or products with strong strategic alignment to the corporation are preferred. The firm prioritizes companies that have a working prototype and ideally are already on the market, generating revenue. However, for equity investments, earlier-stage disruptive technologies may also be considered. 
 
The firm does not have specific requirements regarding a company’s founding team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm invests primarily in very early-stage companies, from pre-seed to seed stages. The firm’s average check size ranges from $250,000 to $500,000. While the firm is focused on the US, particularly in the West Coast, it remains open to global opportunities. The firm is flexible in both lending and co-investing and may seek an observer seat on a case-by-case basis. The firm plays an active role in supporting its portfolio companies, assisting them with concept validation, clinical trials, and navigating reimbursement and regulatory pathways. The firm also provides resources to help companies gather data and evidence for their minimum viable products. 
 
The firm is interested in opportunities across digital therapeutics, diagnostics, and medical devices. Some key indication areas of interest include cardiovascular, metabolic, diabetes, nephropathy, and women’s health. The firm typically focuses on less traditional pharma products, such as compounds and cell-based therapies. The firm prefers to engage with companies at an early stage and will consider those with at least a minimum viable product. 
 
The firm does not have specific requirements for a company’s founding team. However, the firm prefers companies based in the U.S. or those with incentives to relocate to the U.S. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A global corporation and integrated business enterprise is interested in expanding the healthcare business and increasing its presence in the US. The firm seeks to make engage with early and mid-stage healthcare companies through strategic investment, partnerships, and more. The firm is open to global opportunities. 
 
Within life sciences and healthcare sectors, the firm is most interested in medical devices, diagnostics, digital health, and healthcare services. Within medtech, the firm focuses on surgical applications, respiratory/anesthesia, radiology, cardiology, etc. In digital health, technologies addressing areas such as virtual care providers, wellness management, etc. that could benefit the aging population are of interest. The firm is can partner with companies across a wide stage of development, from companies still developing a prototype to those who are already on the market. The firm does not invest in biotech or pharmaceutical companies. 
 
The firm has no specific company or management team requirements. The firm is interested in companies who are looking to enter the Asian market, and can help support the companies in navigating regulatory hurdles by leveraging their own regulatory team. The firm can act as a lead or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.